| Nov 20 |
RANI: Third Quarter Update
|
| Nov 14 |
Rani Therapeutics GAAP EPS of -$0.24 in-line
|
| Nov 14 |
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
|
| Nov 7 |
Rani Therapeutics to Participate in Upcoming Investor Conferences
|
| Oct 23 |
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch
|
| Oct 22 |
RANI: New Triagonist Data in Weight Loss
|
| Oct 17 |
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
|
| Oct 15 |
Top Midday Decliners
|
| Oct 15 |
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering
|
| Oct 15 |
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
|
